CA2419385A1 - Saratin for inhibiting platelet adhesion to collagen - Google Patents
Saratin for inhibiting platelet adhesion to collagen Download PDFInfo
- Publication number
- CA2419385A1 CA2419385A1 CA002419385A CA2419385A CA2419385A1 CA 2419385 A1 CA2419385 A1 CA 2419385A1 CA 002419385 A CA002419385 A CA 002419385A CA 2419385 A CA2419385 A CA 2419385A CA 2419385 A1 CA2419385 A1 CA 2419385A1
- Authority
- CA
- Canada
- Prior art keywords
- saratin
- locally
- tissue
- incorporated
- catheter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
Abstract
Use of the polypeptide Saratin for the manufacture of a medicament having th e capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to a novel medical use of Saratin as an inhibitor of thrombosis and intimal hyperplasia, wherein said polypeptide may be used locally as a topical agent or as a coating on, or otherwise incorporated or associated with medical devices.
Claims (19)
1. Use of the polypeptide Saratin for the manufacture of a medicament for inhibiting platelet accumulation after vascular injuries or endarterectomy comprising administering to the vascular tissue a therapeutically effective amount of Saratin which prevents platelet adhesion, thereby inhibiting thrombosis and restenosis.
2. Use of the method of Claim 1, wherein the vascular injury is associated with atherosclerosis, cardiac transplant vasculopathy, coronary restenosis following coronary intervention, balloon angioplasty, stent placement, rotablation, endarterectomy, including carotid endarterectomy, dialysis graft shunts and other graft anastomoses, unstable angina, acute myocardial infarction, stroke, benign hypertrophy, or benign prostatic hypertrophy
3. Device having a surface covered with a hydrogel incorporating an amount of biologically active Saratin therein for local delivery therefrom and means associated with the coating to provide an anti-thrombogenic surface.
4. Use of the method according to claim 1, wherein the Saratin is administerd locally via a catheter or wherein Saratin is incorporated into endoluminal paving of a catheter which is directed locally to the tissue.
5. Use of the method of Claim 1, wherein Saratin is incorporated into a locally administered polymer that permits local sustained release of Saratin.
6. Use of the method of Claim 5, wherein the polymer formulated Saratin is administerd locally via a catheter.
7. A catheter device characterized in that a polymeric material is part of the device and contains Saratin.
8. Use of the method of Claim 1, wherein Saratin is incorporated into a stent or stent coating which is placed locally on or in the tissue.
9. Use of the method of Claim 1, wherein Saratin is incorporated into an endovascular graft or an endovascular graft coating which is placed locally on or in the tissue.
10. A kit comprising any one of claims 1-9.
Additional claims for US
Additional claims for US
11. A method of treating injured vascular tissue, comprising locally administering to the injured vascular tissue a therapeutically effective, platelet adhesion inhibiting amount of Saratin, thereby treating the injured vascular tissue.
12. The method of Claim 9, wherein the vascular injury is associated with atherosclerosis, cardiac transplant vasculopathy, coronary restenosis following coronary intervention, balloon angioplasty, stent placement, rotablation, endarterectomy including carotid endarterectomy, dialysis graft shunts and other graft anastomoses, unstable angina, acute myocardial infarction, stroke, benign hypertrophy, or benign prostatic hypertrophy.
13. The method of Claim 9, wherein the vascular injury is associated with atherosclerosis or restenosis.
14. The method of Claim 9, wherein Saratin is locally administered via a catheter.
15. The method of Claim 14, wherein Saratin is incorporated into endoluminal paving of a catheter which is directed locally to the tissue.
16. The method of Claim 9, wherein Saratin is incorporated into a locally administered polymer that permits local sustained release of Saratin.
17. The method of Claim 9, wherein the polymer formulated Saratin is administerd locally via a catheter.
18. The method of Claim 9, wherein Saratin is incorporated into a stent or stent coating which is placed locally on or in the tissue.
19. The method of Claim 1, wherein Saratin is incorporated into an endovascular graft or an endovascular graft coating which is placed locally on or in the tissue.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00118542 | 2000-08-25 | ||
| EP00118542.0 | 2000-08-25 | ||
| PCT/EP2001/009746 WO2002015919A2 (en) | 2000-08-25 | 2001-08-23 | Saratin for inhibiting platelet adhesion to collagen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2419385A1 true CA2419385A1 (en) | 2002-02-28 |
| CA2419385C CA2419385C (en) | 2011-05-10 |
Family
ID=8169664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2419385A Expired - Fee Related CA2419385C (en) | 2000-08-25 | 2001-08-23 | Saratin for inhibiting platelet adhesion to collagen |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6881722B2 (en) |
| EP (1) | EP1311284B1 (en) |
| JP (1) | JP4988131B2 (en) |
| KR (1) | KR100794277B1 (en) |
| CN (1) | CN1224421C (en) |
| AR (1) | AR030492A1 (en) |
| AT (1) | ATE285246T1 (en) |
| AU (2) | AU2001295506B2 (en) |
| BR (1) | BR0113478A (en) |
| CA (1) | CA2419385C (en) |
| CZ (1) | CZ302353B6 (en) |
| DE (1) | DE60107962T2 (en) |
| DK (1) | DK1311284T3 (en) |
| EC (1) | ECSP034485A (en) |
| ES (1) | ES2234896T3 (en) |
| HK (1) | HK1059736A1 (en) |
| HU (1) | HU229367B1 (en) |
| MX (1) | MXPA03001604A (en) |
| MY (1) | MY128992A (en) |
| NO (1) | NO331326B1 (en) |
| PT (1) | PT1311284E (en) |
| RU (1) | RU2302880C2 (en) |
| SI (1) | SI1311284T1 (en) |
| SK (1) | SK287829B6 (en) |
| UA (1) | UA77402C2 (en) |
| WO (1) | WO2002015919A2 (en) |
| ZA (1) | ZA200302296B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200102729T2 (en) * | 1999-03-18 | 2002-04-22 | Merck Patent Gmbh | Protein for blocking platelet adhesion |
| KR20080113286A (en) | 2003-01-10 | 2008-12-29 | 아블린쓰 엔.브이. | Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf) or against collagen |
| CN101278012A (en) * | 2005-09-28 | 2008-10-01 | 拜奥瓦斯库勒公司 | Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation |
| US20110034396A1 (en) * | 2005-09-28 | 2011-02-10 | Biovascular, Inc. | Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions |
| US20080069774A1 (en) * | 2005-11-17 | 2008-03-20 | Lance Liotta | Proteomic antisense molecular shield and targeting |
| CN117229423B (en) * | 2023-11-10 | 2024-02-06 | 北京科技大学 | Polypeptide nano material for binding collagen and preparation method and application thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947401A (en) * | 1971-10-05 | 1976-03-30 | Union Optics Corporation | Hydrogels of unsaturated ester copolymers |
| US5705355A (en) * | 1984-03-27 | 1998-01-06 | Transgene, S.A. | Hirudin, pharmaceutical compositions comprising it and their use |
| US4898734A (en) * | 1988-02-29 | 1990-02-06 | Massachusetts Institute Of Technology | Polymer composite for controlled release or membrane formation |
| IL86857A (en) * | 1988-06-24 | 1994-04-12 | Yissum Res Dev Co | Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same |
| US5304121A (en) * | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| CA2052486A1 (en) * | 1990-10-09 | 1992-04-10 | Thomas M. Connolly | Protein for inhibiting collagen-stimulated platelet aggregation |
| GB9022040D0 (en) | 1990-10-10 | 1990-11-21 | Biopharm Ltd | Platelet adhesion inhibitor |
| US5179082A (en) * | 1990-11-13 | 1993-01-12 | Merck & Co., Inc. | Method for blocking platelet adhesion to collagen |
| DE4136513A1 (en) | 1991-11-06 | 1993-05-13 | Basf Ag | NEW THROMBIN INHIBITORIC PROTEIN FROM RUBBER BUGS |
| US5710131A (en) * | 1993-07-01 | 1998-01-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Inhibitor of collagen-stimulated platelet aggregation |
| EP0711158B2 (en) * | 1993-07-29 | 2008-07-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of treating atherosclerosis or restenosis using microtubule stabilizing agent |
| US5532287A (en) * | 1994-05-04 | 1996-07-02 | Ciba-Geigy Corporation | Radiation cured drug release controlling membrane |
| US6246715B1 (en) * | 1998-06-26 | 2001-06-12 | Samsung Electronics Co., Ltd. | Data transmitter and receiver of a DS-CDMA communication system |
| US5843172A (en) * | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
| WO2000023094A2 (en) * | 1998-10-16 | 2000-04-27 | Immunex Corporation | Methods of inhibiting platelet activation and recruitment |
| IT1304135B1 (en) * | 1998-11-26 | 2001-03-07 | Magneti Marelli Spa | INJECTION AND IGNITION CONTROL METHOD IN A DIRECT INJECTION THERMAL ENGINE TO ACCELERATE THE HEATING OF THE |
| US6448221B1 (en) * | 1999-02-19 | 2002-09-10 | Zymogenetics, Inc. | Methods of promoting blood flow within the vasculature of a mammal |
| TR200102729T2 (en) * | 1999-03-18 | 2002-04-22 | Merck Patent Gmbh | Protein for blocking platelet adhesion |
-
2001
- 2001-08-22 MY MYPI20013935A patent/MY128992A/en unknown
- 2001-08-23 UA UA2003032476A patent/UA77402C2/en unknown
- 2001-08-23 DE DE60107962T patent/DE60107962T2/en not_active Expired - Lifetime
- 2001-08-23 CN CNB018146600A patent/CN1224421C/en not_active Expired - Fee Related
- 2001-08-23 MX MXPA03001604A patent/MXPA03001604A/en active IP Right Grant
- 2001-08-23 BR BR0113478-7A patent/BR0113478A/en not_active Application Discontinuation
- 2001-08-23 HU HU0303747A patent/HU229367B1/en not_active IP Right Cessation
- 2001-08-23 SK SK313-2003A patent/SK287829B6/en not_active IP Right Cessation
- 2001-08-23 CA CA2419385A patent/CA2419385C/en not_active Expired - Fee Related
- 2001-08-23 AT AT01976139T patent/ATE285246T1/en active
- 2001-08-23 JP JP2002520840A patent/JP4988131B2/en not_active Expired - Fee Related
- 2001-08-23 AU AU2001295506A patent/AU2001295506B2/en not_active Ceased
- 2001-08-23 RU RU2003107919/15A patent/RU2302880C2/en not_active IP Right Cessation
- 2001-08-23 AU AU9550601A patent/AU9550601A/en active Pending
- 2001-08-23 DK DK01976139T patent/DK1311284T3/en active
- 2001-08-23 US US10/362,476 patent/US6881722B2/en not_active Expired - Fee Related
- 2001-08-23 WO PCT/EP2001/009746 patent/WO2002015919A2/en active IP Right Grant
- 2001-08-23 SI SI200130310T patent/SI1311284T1/xx unknown
- 2001-08-23 EP EP01976139A patent/EP1311284B1/en not_active Expired - Lifetime
- 2001-08-23 CZ CZ20030720A patent/CZ302353B6/en not_active IP Right Cessation
- 2001-08-23 PT PT01976139T patent/PT1311284E/en unknown
- 2001-08-23 KR KR1020037002188A patent/KR100794277B1/en not_active IP Right Cessation
- 2001-08-23 ES ES01976139T patent/ES2234896T3/en not_active Expired - Lifetime
- 2001-08-27 AR ARP010104073A patent/AR030492A1/en not_active Application Discontinuation
-
2003
- 2003-02-21 EC EC2003004485A patent/ECSP034485A/en unknown
- 2003-02-24 NO NO20030841A patent/NO331326B1/en not_active IP Right Cessation
- 2003-03-24 ZA ZA200302296A patent/ZA200302296B/en unknown
-
2004
- 2004-04-14 HK HK04102595A patent/HK1059736A1/en not_active IP Right Cessation
- 2004-12-21 US US11/016,854 patent/US7459438B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1802361B1 (en) | Angiotensin-(1-7) eluting polymer-coated medical device to reduce restenosis and improve endothelial cell function | |
| Van Belle et al. | Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation | |
| WO2003009779A3 (en) | Delivery of therapeutic capable agents | |
| CA2408838A1 (en) | Drug/drug delivery systems for the prevention and treatment of vascular disease | |
| WO2004069201A3 (en) | Compounds useful in coating stents to prevent and treat stenosis and restenosis | |
| WO2005051229A3 (en) | Devices delivering therapeutic agents and methods regarding the same | |
| BR9811000A (en) | "polymeric compositions" | |
| WO2003024455A3 (en) | Stent coated with a sustained-release drug delivery and method for use thereof | |
| BR9808109A (en) | Therapeutic smooth muscle vascular cell inhibitor | |
| DE60130032D1 (en) | Device for delivery of therapeutic agents | |
| CA2468254A1 (en) | Therapeutic coating for an intravascular implant | |
| ATE298590T1 (en) | BIOACTIVE ACTIVE COATINGS | |
| WO2002017880A3 (en) | Nitric oxide-producing hydrogel materials | |
| MXPA03010085A (en) | Composition and methods for treatment of hyperplasia. | |
| CA2490170A1 (en) | Local vascular delivery of trichostatin a alone or in combination with sirolimus to prevent restenosis following vascular injury | |
| EP1812091A2 (en) | Biocompatible and hemocompatible amphiphilic coatings for drug delivery | |
| CA2162587A1 (en) | Therapeutic inhibitor of vascular smooth muscle cells | |
| US20070112406A1 (en) | Platforms, particularly prostheses, having biologically active coverings | |
| CA2419385A1 (en) | Saratin for inhibiting platelet adhesion to collagen | |
| Orloff et al. | Biodegradable implant strategies for inhibition of restenosis | |
| PL335046A1 (en) | Method of and agent for treating arteriosclerosis and vascular lesions by preventing proliferation of smooth muscle vascular fibres | |
| WO2002087472A8 (en) | Stent-based delivery of statins to prevent restenosis | |
| Muller et al. | Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting | |
| RU2003107919A (en) | A NEW SPECIFIC MECHANISM FOR THE INHIBITION OF ADHESION OF THROMBOCYTES TO COLLAGEN | |
| JP2004506690A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160823 |